Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 134Breast Neoplasms 94Colorectal Neoplasms 66Carcinoma, Hepatocellular 57Squamous Cell Carcinoma of Head and Neck 48Stomach Neoplasms 46Prostatic Neoplasms 45Lung Neoplasms 45Triple Negative Breast Neoplasms 43Leukemia, Myeloid, Acute 43Uterine Cervical Neoplasms 41Small Cell Lung Carcinoma 41Rectal Neoplasms 37Neoplasms 32Pancreatic Neoplasms 30Neoplasm Metastasis 30Recurrence 28Ovarian Neoplasms 25Esophageal Squamous Cell Carcinoma 25Esophageal Neoplasms 24Nasopharyngeal Carcinoma 21Endometrial Neoplasms 21Brain Neoplasms 21Melanoma 20Lymphoma, Large B-Cell, Diffuse 20Head and Neck Neoplasms 20Colonic Neoplasms 20Carcinoma, Renal Cell 19Biliary Tract Neoplasms 18Multiple Myeloma 17

Interventions

Radiotherapy 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Not yet recruiting × HER2-Negative Locally Advanced Breast Cancer × Clear all
NCT06908668 2025-04-03

Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
170 enrolled
Breast

HER2-Negative Locally Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡